Drugs / SIM0686
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07050459 | May 2025 → Dec 2027 expected | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-07-21 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory Novel FGFR2b-targeting ADC is approved by the U.S. FDA to enter clinical trials simcere.com ↗ |
| 2025-04-10 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory Simcere Zaiming’s FGFR2b targeting ADC SIM0686 obtained IND approval from China NMPA simcere.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-21 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Novel FGFR2b-targeting ADC is approved by the U.S. FDA to enter clinical trials simcere.com ↗ |
| 2025-04-10 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere Zaiming’s FGFR2b targeting ADC SIM0686 obtained IND approval from China NMPA simcere.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM0686 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07050459 ↗ |
| Route | Intravenous | “Administered intravenously” NCT07050459 ↗ |